Doxazosin Mesylate API

Name	Doxazosin mesylate
Chinese name	甲磺酸多沙唑嗪
Cas Number	77883-43-3
Source	India
Qualifications	-/-/-/-/-

Doxazosin mesylate is a new generation of quinazolone alpha 1 receptor blocker developed and marketed by Pfizer. It was approved by the FDA in 1995 for the treatment of benign prostatic hyperplasia. It was launched in China in September 2002. It has become the first-line drug for the treatment of mild to moderate hypertension at home and abroad, and the first-line drug for the treatment of benign prostatic hyperplasia with lower urinary tract symptoms (BPH/LUTS). Doxazosin mesylate selectively acts on post-ganglionic α1-adrenergic receptors, acting on the a1-adrenergic receptors of the smooth muscles of the prostate and bladder neck, and relaxes the smooth muscles of the bladder neck, prostate and prostate capsule, urethra and bladder Resistance is reduced, thereby reducing the symptoms of urethral obstruction caused by prostate hyperplasia. Clinical pharmacological experiments have proved that finasteride and doxazosin can be used in combination and have a synergistic effect. Compared with finasteride alone, the combination of the two drugs significantly reduces the progression of prostate hyperplasia Incidence rate and delay the progression of prostate hyperplasia. A clinical study pointed out that patients with type 2 diabetes found that their regulatory T cells increased after being given doxazosin for 3 months, confirming that doxazosin has an immunomodulatory effect on type 2 diabetes.

Hot Tags: doxazosin mesylate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Brinzolamide API, Canagliflozin API, Edoxaban API, Bemeprost API, Troxagliptin Succinate API, Lercanidipine Hydrochloride API

• Previous: Milnacipran Hydrochloride API
• Next: Iron Sucrose API